The European Patent Office grants key patent in the stem cell field

24.03.2015

On 22nd January the European Patent Office (EPO) announced the european patent EP2292736 is granted to TiGenix, a leading biopharmaceutical company based on Leuven (Belgium) and operating in Madrid (Spain), focused on developing and commercialising innovative cell therapies. This patent protects a specified population of adipose-derived multipotent cells  and their therapeutic uses, as well as pharmaceutical compositions of such cells.

The Belgian company has been developing a stem cell programme, in close consultation with the European Medicines Agency (EMA), focused on two products: Cx601 and Cx611. The first one is currently in the third phase of   European clinical tests and is addressed to patients with Crohn’s disease. The company intends to get commercial acceptation in Europe if the final results are positive. The aim of the second product is the treatment of patients with early rheumatoid arthritis and those who suffer from severe sepsis. 

The European patent, entitled “Identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue”, consolidates the leading position of TiGenix in the biomedical field and reinforces their intellectual property portfolio, which already includes 14 certificated patents on its aplatform of allogeneic stem cell expanding derived from adipose tissue.

The granting of this patent is a positive step on stem in the field of stem cell therapy in Europe, along with the decision of the European Court of Justice (ECJ) last December in favor of International Stem Cell Corporation (ISCO). The world leader in research into human stem cell, non-embryonic, filed two patent applications in 2011, that were rejected by the United Kingdom Intellectual Property Office (UKIPO), alleging that they violated the patentable methods allowed by the Directive 98/44/EC on the legal protection of biotechnological inventions. The ECJ rejected UKIPO’s allegations and has allowed ISCO to present patents applications, if only embryonic stem cells are derived from unfertilized eggs.

Written by: María Vega

Image: Michael, under Creative Commons license CC BY-NC 2.0 https://www.flickr.com/photos/michlt/1480251442

Sources:

http://www.tigenix.com/es

http://ipfrontline.com/2015/01/european-patent-office-issues-key-patent-to-tigenix/

http://elpais.com/elpais/2014/12/18/ciencia/1418928433_575443.html

http://www.internationalstemcell.com/profiles/investor/ResLibraryView.asp?ResLibraryID=74444&GoTopage=1&Category=958&BzID=1468&G=583



© 2003 uaipit.com. Tous droits réservés. ® Marque Communauté déposée 2003. Université d'Alicante.

Portail juridique: sur marque, brevet , droit, infractions au code pénal , le droit , le droit international , la propriété intellectuelle , la propriété industrielle, mediation
Ce site utilise des cookies...+info